Capital Asset Pricing Model (CAPM)
Capital asset pricing model (CAPM) indicates what should be the expected or required rate of return on risky assets like Regeneron Pharmaceuticals Inc. common stock.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Assets (ROA) since 2005
- Current Ratio since 2005
- Price to Sales (P/S) since 2005
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Rates of Return
Regeneron Pharmaceuticals Inc., monthly rates of return
| Regeneron Pharmaceuticals Inc. (REGN) | Standard & Poor’s 500 (S&P 500) | |||||
|---|---|---|---|---|---|---|
| t | Date | PriceREGN,t1 | DividendREGN,t1 | RREGN,t2 | PriceS&P 500,t | RS&P 500,t3 |
| Jan 31, 2019 | ||||||
| 1. | Feb 28, 2019 | |||||
| 2. | Mar 31, 2019 | |||||
| 3. | Apr 30, 2019 | |||||
| . | . | . | . | . | . | . |
| . | . | . | . | . | . | . |
| . | . | . | . | . | . | . |
| 58. | Nov 30, 2023 | |||||
| 59. | Dec 31, 2023 | |||||
| Average (R): | ||||||
| Standard deviation: | ||||||
| Regeneron Pharmaceuticals Inc. (REGN) | Standard & Poor’s 500 (S&P 500) | |||||
|---|---|---|---|---|---|---|
| t | Date | PriceREGN,t1 | DividendREGN,t1 | RREGN,t2 | PriceS&P 500,t | RS&P 500,t3 |
| Jan 31, 2019 | ||||||
| 1. | Feb 28, 2019 | |||||
| 2. | Mar 31, 2019 | |||||
| 3. | Apr 30, 2019 | |||||
| 4. | May 31, 2019 | |||||
| 5. | Jun 30, 2019 | |||||
| 6. | Jul 31, 2019 | |||||
| 7. | Aug 31, 2019 | |||||
| 8. | Sep 30, 2019 | |||||
| 9. | Oct 31, 2019 | |||||
| 10. | Nov 30, 2019 | |||||
| 11. | Dec 31, 2019 | |||||
| 12. | Jan 31, 2020 | |||||
| 13. | Feb 29, 2020 | |||||
| 14. | Mar 31, 2020 | |||||
| 15. | Apr 30, 2020 | |||||
| 16. | May 31, 2020 | |||||
| 17. | Jun 30, 2020 | |||||
| 18. | Jul 31, 2020 | |||||
| 19. | Aug 31, 2020 | |||||
| 20. | Sep 30, 2020 | |||||
| 21. | Oct 31, 2020 | |||||
| 22. | Nov 30, 2020 | |||||
| 23. | Dec 31, 2020 | |||||
| 24. | Jan 31, 2021 | |||||
| 25. | Feb 28, 2021 | |||||
| 26. | Mar 31, 2021 | |||||
| 27. | Apr 30, 2021 | |||||
| 28. | May 31, 2021 | |||||
| 29. | Jun 30, 2021 | |||||
| 30. | Jul 31, 2021 | |||||
| 31. | Aug 31, 2021 | |||||
| 32. | Sep 30, 2021 | |||||
| 33. | Oct 31, 2021 | |||||
| 34. | Nov 30, 2021 | |||||
| 35. | Dec 31, 2021 | |||||
| 36. | Jan 31, 2022 | |||||
| 37. | Feb 28, 2022 | |||||
| 38. | Mar 31, 2022 | |||||
| 39. | Apr 30, 2022 | |||||
| 40. | May 31, 2022 | |||||
| 41. | Jun 30, 2022 | |||||
| 42. | Jul 31, 2022 | |||||
| 43. | Aug 31, 2022 | |||||
| 44. | Sep 30, 2022 | |||||
| 45. | Oct 31, 2022 | |||||
| 46. | Nov 30, 2022 | |||||
| 47. | Dec 31, 2022 | |||||
| 48. | Jan 31, 2023 | |||||
| 49. | Feb 28, 2023 | |||||
| 50. | Mar 31, 2023 | |||||
| 51. | Apr 30, 2023 | |||||
| 52. | May 31, 2023 | |||||
| 53. | Jun 30, 2023 | |||||
| 54. | Jul 31, 2023 | |||||
| 55. | Aug 31, 2023 | |||||
| 56. | Sep 30, 2023 | |||||
| 57. | Oct 31, 2023 | |||||
| 58. | Nov 30, 2023 | |||||
| 59. | Dec 31, 2023 | |||||
| Average (R): | ||||||
| Standard deviation: | ||||||
Show all
1 Data in US$ per share of common stock, adjusted for splits and stock dividends.
2 Rate of return on common stock of REGN during period t
3 Rate of return on S&P 500 (the market portfolio proxy) during period t
Variance and Covariance
Regeneron Pharmaceuticals Inc., calculation of variance and covariance of returns
| t | Date | RREGN,t | RS&P 500,t | (RREGN,t–RREGN)2 | (RS&P 500,t–RS&P 500)2 | (RREGN,t–RREGN)×(RS&P 500,t–RS&P 500) |
|---|---|---|---|---|---|---|
| 1. | Feb 28, 2019 | |||||
| 2. | Mar 31, 2019 | |||||
| 3. | Apr 30, 2019 | |||||
| . | . | . | . | . | . | . |
| . | . | . | . | . | . | . |
| . | . | . | . | . | . | . |
| 58. | Nov 30, 2023 | |||||
| 59. | Dec 31, 2023 | |||||
| Total (Σ): | ||||||
| t | Date | RREGN,t | RS&P 500,t | (RREGN,t–RREGN)2 | (RS&P 500,t–RS&P 500)2 | (RREGN,t–RREGN)×(RS&P 500,t–RS&P 500) |
|---|---|---|---|---|---|---|
| 1. | Feb 28, 2019 | |||||
| 2. | Mar 31, 2019 | |||||
| 3. | Apr 30, 2019 | |||||
| 4. | May 31, 2019 | |||||
| 5. | Jun 30, 2019 | |||||
| 6. | Jul 31, 2019 | |||||
| 7. | Aug 31, 2019 | |||||
| 8. | Sep 30, 2019 | |||||
| 9. | Oct 31, 2019 | |||||
| 10. | Nov 30, 2019 | |||||
| 11. | Dec 31, 2019 | |||||
| 12. | Jan 31, 2020 | |||||
| 13. | Feb 29, 2020 | |||||
| 14. | Mar 31, 2020 | |||||
| 15. | Apr 30, 2020 | |||||
| 16. | May 31, 2020 | |||||
| 17. | Jun 30, 2020 | |||||
| 18. | Jul 31, 2020 | |||||
| 19. | Aug 31, 2020 | |||||
| 20. | Sep 30, 2020 | |||||
| 21. | Oct 31, 2020 | |||||
| 22. | Nov 30, 2020 | |||||
| 23. | Dec 31, 2020 | |||||
| 24. | Jan 31, 2021 | |||||
| 25. | Feb 28, 2021 | |||||
| 26. | Mar 31, 2021 | |||||
| 27. | Apr 30, 2021 | |||||
| 28. | May 31, 2021 | |||||
| 29. | Jun 30, 2021 | |||||
| 30. | Jul 31, 2021 | |||||
| 31. | Aug 31, 2021 | |||||
| 32. | Sep 30, 2021 | |||||
| 33. | Oct 31, 2021 | |||||
| 34. | Nov 30, 2021 | |||||
| 35. | Dec 31, 2021 | |||||
| 36. | Jan 31, 2022 | |||||
| 37. | Feb 28, 2022 | |||||
| 38. | Mar 31, 2022 | |||||
| 39. | Apr 30, 2022 | |||||
| 40. | May 31, 2022 | |||||
| 41. | Jun 30, 2022 | |||||
| 42. | Jul 31, 2022 | |||||
| 43. | Aug 31, 2022 | |||||
| 44. | Sep 30, 2022 | |||||
| 45. | Oct 31, 2022 | |||||
| 46. | Nov 30, 2022 | |||||
| 47. | Dec 31, 2022 | |||||
| 48. | Jan 31, 2023 | |||||
| 49. | Feb 28, 2023 | |||||
| 50. | Mar 31, 2023 | |||||
| 51. | Apr 30, 2023 | |||||
| 52. | May 31, 2023 | |||||
| 53. | Jun 30, 2023 | |||||
| 54. | Jul 31, 2023 | |||||
| 55. | Aug 31, 2023 | |||||
| 56. | Sep 30, 2023 | |||||
| 57. | Oct 31, 2023 | |||||
| 58. | Nov 30, 2023 | |||||
| 59. | Dec 31, 2023 | |||||
| Total (Σ): | ||||||
Show all
VarianceREGN = Σ(RREGN,t–RREGN)2 ÷ (59 – 1)
= ÷ (59 – 1)
=
VarianceS&P 500 = Σ(RS&P 500,t–RS&P 500)2 ÷ (59 – 1)
= ÷ (59 – 1)
=
CovarianceREGN, S&P 500 = Σ(RREGN,t–RREGN)×(RS&P 500,t–RS&P 500) ÷ (59 – 1)
= ÷ (59 – 1)
=
Systematic Risk (β) Estimation
| VarianceREGN | |
| VarianceS&P 500 | |
| CovarianceREGN, S&P 500 | |
| Correlation coefficientREGN, S&P 5001 | |
| βREGN2 | |
| αREGN3 |
Calculations
1 Correlation coefficientREGN, S&P 500
= CovarianceREGN, S&P 500 ÷ (Standard deviationREGN × Standard deviationS&P 500)
= ÷ ( × )
=
2 βREGN
= CovarianceREGN, S&P 500 ÷ VarianceS&P 500
= ÷
=
3 αREGN
= AverageREGN – βREGN × AverageS&P 500
= – ×
=
Expected Rate of Return
| Assumptions | ||
| Rate of return on LT Treasury Composite1 | RF | |
| Expected rate of return on market portfolio2 | E(RM) | |
| Systematic risk (β) of Regeneron Pharmaceuticals Inc. common stock | βREGN | |
| Expected rate of return on Regeneron Pharmaceuticals Inc. common stock3 | E(RREGN) | |
1 Unweighted average of bid yields on all outstanding fixed-coupon U.S. Treasury bonds neither due or callable in less than 10 years (risk-free rate of return proxy).
3 E(RREGN) = RF + βREGN [E(RM) – RF]
= + [ – ]
=